The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2022 | Improving risk stratification models for patients with MGUS and smoldering myeloma
In this video, Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, briefly discusses reasons for improving risk stratification models for patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma and the goal of these novel models in preventing disease progression. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
